Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTA), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pasithea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pasithea Therapeutics's position in the market.
Pasithea Therapeutics (NASDAQ: KTTA) has closed its previously announced public offering, raising total gross proceeds of approximately $6.3 million. The offering consisted of 3,571,428 shares of common stock (or pre-funded warrants) and accompanying Series C and D warrants at $1.40 per share. The company received $5.0 million from the initial offering and an additional $1.3 million from the immediate exercise of Series D warrants by certain investors.
The Series C warrants have a 5-year term while Series D warrants expire in 18 months, both with an exercise price of $1.40 per share. H.C. Wainwright & Co. served as the exclusive placement agent. The funds will support general corporate purposes, including research, clinical trials, technology development, potential acquisitions, and working capital.
Pasithea Therapeutics (NASDAQ: KTTA) has announced the pricing of a $5 million public offering consisting of 3,571,428 shares of common stock (or pre-funded warrants) at $1.40 per share. The offering includes accompanying Series C warrants (5-year expiration) and Series D warrants (18-month expiration), both with an exercise price of $1.40 per share.
H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around May 7, 2025. The company plans to use the proceeds for general corporate purposes, including research, clinical trials, technology development, potential acquisitions, and working capital. Pasithea is developing PAS-004, a next-generation macrocyclic MEK inhibitor for neurofibromatosis type 1 and other cancer indications.
Pasithea Therapeutics (NASDAQ: KTTA) has reached a significant milestone in its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor. The company has successfully completed enrollment and initial dosing of three subjects in Cohort 6, administering 30 mg capsules of PAS-004.
The ongoing trial is designed as a multi-center, open-label, dose escalation 3+3 study, focusing on patients with MAPK pathway driven advanced solid tumors. The study specifically targets patients with documented RAS, NF1, or RAF mutations, or those who have not responded to BRAF/MEK inhibition.
CEO Dr. Tiago Reis Marques expressed satisfaction with the rapid recruitment and enrollment pace, projecting complete trial enrollment by the end of 2025. The study aims to evaluate multiple aspects of PAS-004, including:
- Safety and tolerability
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
- Preliminary efficacy
Pasithea Therapeutics (NASDAQ: KTTA) has announced that it will present updated interim clinical data from its ongoing Phase 1 trial of PAS-004, a next-generation macrocyclic MEK inhibitor, at the 2025 ASCO Annual Meeting in Chicago. The presentation will take place on June 2, 2025, from 1:30 – 4:30 PM CDT.
The trial focuses on patients with MAPK pathway driven advanced solid tumors and has shown promising results through cohorts 4A and 4B, demonstrating clinical activity, target engagement, and a favorable safety profile. PAS-004 is being developed for treating neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications.
The Phase 1 clinical trial (NCT06299839) is designed as a multi-center, open-label, dose escalation 3+3 study, evaluating safety, tolerability, pharmacokinetic, pharmacodynamic, and preliminary efficacy in patients with documented RAS, NF1 or RAF mutations, or those who have failed BRAF/MEK inhibition.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive progress in its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancers. The Safety Review Committee recommended advancing to Cohort 6 with a 30mg capsule dose following review of Cohort 5 data.
Key highlights include:
- No dose-limiting toxicities (DLTs) observed across 19 patients
- Zero instances of rash reported during the DLT period
- Strong enrollment demand with Cohort 6 patients already identified
The trial (NCT06299839) is a multi-center, open-label, dose escalation study evaluating PAS-004's safety, tolerability, and preliminary efficacy in patients with MAPK pathway driven advanced solid tumors. The company plans to release additional safety, pharmacokinetic, and pharmacodynamic data in the coming weeks.
Pasithea Therapeutics (NASDAQ: KTTA) has announced its participation in the upcoming 2025 CAGLA NeauxCancer Conference, a leading global oncology forum scheduled for March 27-29, 2025, in New Orleans.
The company's Vice President of Business Development, Mathew Lazarus, will present on March 28 at 11:00 AM CDT at The Roosevelt Hotel. His presentation will focus on PAS-004, the company's next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 (NF1) and other cancer indications.
The presentation will include interim data from their ongoing Phase 1 study, covering safety, tolerability, and pharmacokinetic (PK) results in advanced cancer patients with MAPK pathway-driven tumors. Lazarus will also discuss Pasithea's progress in clinical development and their strategy to revolutionize cancer and NF1 treatment.
Pasithea Therapeutics (NASDAQ: KTTA) announced positive safety review recommendations for its Phase 1 clinical trial of PAS-004, advancing to cohort 5 with a 22mg capsule dose. The trial, evaluating a next-generation macrocyclic MEK inhibitor for neurofibromatosis type 1 (NF1) and other cancers, showed no dose-limiting toxicities in cohort 4A (15mg capsule) patients.
Notably, none of the 14 patients treated with PAS-004 (12 capsule, 2 tablet formulations) experienced rash, a common side effect with competitor MEK inhibitors that often leads to treatment discontinuation. The drug demonstrates a half-life exceeding 60 hours and substantial exposure levels. The ongoing multi-center, open-label study (NCT06299839) evaluates safety, tolerability, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors with RAS, NF1, or RAF mutations.
Pasithea Therapeutics (NASDAQ: KTTA) has expanded its Phase 1 clinical trial for PAS-004, a next-generation macrocyclic MEK inhibitor, by opening three new sites in Eastern Europe. The trial now includes locations in Romania and Bulgaria, operating alongside four existing U.S. sites. The company has completed initial dosing of three patients in Cohort 4A (15mg capsule) and is currently recruiting for Cohort 4B (4mg tablet).
The ongoing trial is a multi-center, open-label, dose-escalation study evaluating PAS-004's safety, tolerability, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors. The company expects to present interim safety and pharmacokinetic data from Cohorts 4A and 4B in Q1 2025.